[1] Gordon C.Long-term complications of systemic lupus erythematosus.Rheumatology (Oxford),2002,41:1095-1100. [2] Kipen Y,Buchbinder R,Forbes A,et al.Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids.J Rheumatol,1997,24:1922-1929. [3] 吴铁,李青南,胡彬,等.壮骨胶囊防治类固醇大鼠肾阳虚的实验研究.中国骨质疏松杂志,1999,5:76-82. [4] 吴铁,崔燎,陈志东,等.壮骨肾宝对抗泼尼松不良的实验研究.中国中医药科技,1996,3:16-19. [5] Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.Report of a WHO Study Group.World Health Organ Tech Rep Ser,1994,843:1-129. [6] Star VL,Hochberg MC.Osteoporosis in patients with rheumatic diseases.Rheum Dis Clin North Am,1994,20:561-576. [7] Rifas L.Bone and cytokines:beyond IL-1,IL-6 and TNF-alpha.CalcifTissue Int,1999,64:1-7. [8] Di Munno O,Mazzantini M,Delle Sedie A,et al.Risk factors for osteoporosis in female patients with systemic lupus erythematosus.Lupus,2004,13:724-730. [9] 吴铁,崔燎,张志平,等.淫羊藿对抗肾上腺皮质激素不良反应的实验研究.中国中药杂志,1996,21:748-751. |